Anti-Ret antibody (ab51122)

Overview

  • Product nameAnti-Ret antibody
    See all Ret primary antibodies
  • Description
    Rabbit polyclonal to Ret
  • Specificityab51122 detects endogenous levels of total Ret protein.
  • Tested applicationsSuitable for: WB, ELISA, IHC-P, ICC/IFmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    A synthetic non-phosphopeptide derived from human Ret around the phosphorylation site of tyrosine 1062 (K-L-Y-G-M).

  • Positive control
    • K562 cell extracts

Properties

Associated products

Applications

Our Abpromise guarantee covers the use of ab51122 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500 - 1/1000. Predicted molecular weight: 124 kDa.
ELISA 1/10000.
IHC-P Use a concentration of 5 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
ICC/IF Use a concentration of 1 - 5 µg/ml.

Target

  • FunctionProbable receptor with tyrosine-protein kinase activity; important for development.
  • Involvement in diseaseDefects in RET may be a cause of colorectal cancer (CRC) [MIM:114500].
    Defects in RET are a cause of Hirschsprung disease (HSCR) [MIM:142623]. HSCR is a genetic disorder of neural crest development characterized by the absence of intramural ganglion cells in the hindgut, often resulting in intestinal obstruction. Occasionally, MEN2A or FMTC occur in association with HSCR.
    Defects in RET are the cause of medullary thyroid carcinoma (MTC) [MIM:155240]. MTC is a rare tumor derived from the C cells of the thyroid. Three hereditary forms are known, that are transmitted in an autosomal dominant fashion: (a) multiple neoplasia type 2A (MEN2A), (b) multiple neoplasia type IIB (MEN2B) and (c) familial MTC (FMTC), which occurs in 25-30% of MTC cases and where MTC is the only clinical manifestation.
    Defects in RET are the cause of multiple neoplasia type 2B (MEN2B) [MIM:162300]. MEN2B is an uncommon inherited cancer syndrome characterized by predisposition to MTC and phaeochromocytoma which is associated with marfanoid habitus, mucosal neuromas, skeletal and ophtalmic abnormalities, and ganglioneuromas of the intestine tract. Then the disease progresses rapidly with the development of metastatic MTC and a pheochromocytome in 50% of cases.
    Defects in RET are a cause of susceptibility to pheochromocytoma (PCC) [MIM:171300]. A catecholamine-producing tumor of chromaffin tissue of the adrenal medulla or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of epinephrine and norepinephrine, is hypertension, which may be persistent or intermittent.
    Defects in RET are the cause of multiple neoplasia type 2A (MEN2A) [MIM:171400]; also known as multiple neoplasia type 2 (MEN2). MEN2A is the most frequent form of medullary thyroid cancer (MTC). It is an inherited cancer syndrome characterized by MTC, phaeochromocytoma and/or hyperparathyroidism.
    Defects in RET are a cause of thyroid papillary carcinoma (TPC) [MIM:188550]. TPC is a common tumor of the thyroid that typically arises as an irregular, solid or cystic mass from otherwise normal thyroid tissue. Papillary carcinomas are malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. Note=Chromosomal aberrations involving RET are found in thyroid papillary carcinomas. Inversion inv(10)(q11.2;q21) generates the RET/CCDC6 (PTC1) oncogene; inversion inv(10)(q11.2;q11.2) generates the RET/NCOA4 (PTC3) oncogene; translocation t(10;14)(q11;q32) with GOLGA5 generates the RET/GOLGA5 (PTC5) oncogene; translocation t(8;10)(p21.3;q11.2) with PCM1 generates the PCM1/RET fusion; translocation t(6;10)(p21.3;q11.2) with RFP generates the Delta RFP/RET oncogene; translocation t(1;10)(p13;q11) with TRIM33 generates the TRIM33/RET (PTC7) oncogene; translocation t(7;10)(q32;q11) with TRIM24/TIF1 generates the TRIM24/RET (PTC6) oncogene. The PTC5 oncogene has been found in 2 cases of PACT in children exposed to radioactive fallout after Chernobyl. A chromosomal aberration involving TRIM27/RFP is found in thyroid papillary carcinomas. Translocation t(6;10)(p21.3;q11.2) with RET. The translocation generates TRIM27/RET and delta TRIM27/RET oncogenes.
    Defects in RET are a cause of renal adysplasia (RADYS) [MIM:191830]; also known as renal agenesis or renal aplasia. Renal agenesis refers to the absence of one (unilateral) or both (bilateral) kidneys at birth. Bilateral renal agenesis belongs to a group of perinatally lethal renal diseases, including severe bilateral renal dysplasia, unilateral renal agenesis with contralateral dysplasia and severe obstructive uropathy.
    Defects in RET are a cause of congenital central hypoventilation syndrome (CCHS) [MIM:209880]; also known as congenital failure of autonomic control or Ondine curse. CCHS is a rare disorder characterized by abnormal control of respiration in the absence of neuromuscular or lung disease, or an identifiable brain stem lesion. A deficiency in autonomic control of respiration results in inadequate or negligible ventilatory and arousal responses to hypercapnia and hypoxemia.
  • Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family.
    Contains 1 cadherin domain.
    Contains 1 protein kinase domain.
  • Post-translational
    modifications
    Autophosphorylated on C-terminal tyrosine residues upon ligand stimulation. Dephosphorylated by PTPRJ on Tyr-905, Tyr-1015 and Tyr-1062.
  • Cellular localizationMembrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • C ret antibody
    • Cadherin family member 12 antibody
    • Cadherin related family member 16 antibody
    • CDHF 12 antibody
    • CDHF12 antibody
    • CDHR16 antibody
    • ELKS Fusion gene antibody
    • HSCR 1 antibody
    • HSCR1 antibody
    • Hydroxyaryl protein kinase antibody
    • MEN2A antibody
    • MEN2B antibody
    • MTC 1 antibody
    • MTC1 antibody
    • Multiple endocrine neoplasia and medullary thyroid carcinoma 1 antibody
    • Oncogene RET antibody
    • Proto oncogene tyrosine protein kinase receptor ret antibody
    • Proto-oncogene c-Ret antibody
    • Proto-oncogene tyrosine-protein kinase receptor ret antibody
    • PTC antibody
    • RET antibody
    • RET ELE1 antibody
    • Ret Proto oncogene antibody
    • RET transforming sequence antibody
    • RET_HUMAN antibody
    • RET51 antibody
    • RET9 antibody
    • tyrosine-protein kinase receptor ret antibody
    see all

Anti-Ret antibody images

  • All lanes : Anti-Ret antibody (ab51122) at 1/500 dilution

    Lane 1 : K562 Lysate
    Lane 2 : K562 Lysate. For this panel ab51122 was pre-incubated with the immunizing peptide.


    Predicted band size : 124 kDa
  • ICC/IF image of ab51122 stained MCF7 cells. The cells were 4% PFA fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab51122, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

  • IHC image of ab51122 staining in human testis formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab51122, 5µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.

    For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.

References for Anti-Ret antibody (ab51122)

ab51122 has not yet been referenced specifically in any publications.

Product Wall

Thank you for contacting us.

Antibodies in general can be or are glycosylated, but we do not have any data on which of our antibodies are glycosylated and which might not be. We do not usually sequence or investigate the structure of our ant...

Read More

x
I am very pleased to hear you would like to accept our offer and test ab51122 in IHC-Fr. You will not need to mention this code on the order of ab51122. You will need to mention the code when submitting the Abreview and when claiming the free ant...

Read More

Thank you very much for your interest in ab51122.
To our knowledge, ab51122 has not been tested in IHC-Fr. Therefore, I can offer a discount off a future purchase if you buy ab51122 now, test it in IHC-Fr and submit feedback to us in the form of a...

Read More

Thank you for your telephone call this afternoon and for your interest in our products. As far as we are aware, I am sorry to confirm that ab51122  Ret antibody  has not been tested in IP.  All tested applications and speciesare specified on our da...

Read More
Abcam has not validated the combination of species/application used in this Abreview.
Application Western blot
Sample Zebrafish Cell lysate - whole cell (whole embryos at 33hpf and 55hpf)
Loading amount 20 µg
Specification whole embryos at 33hpf and 55hpf
Gel Running Conditions Reduced Denaturing (10% gel)
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C
Username

Dr. robert knight

Verified customer

Submitted Aug 05 2010

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"